0001193125-20-134315.txt : 20200506 0001193125-20-134315.hdr.sgml : 20200506 20200506071729 ACCESSION NUMBER: 0001193125-20-134315 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200506 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200506 DATE AS OF CHANGE: 20200506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Allergan plc CENTRAL INDEX KEY: 0001578845 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36867 FILM NUMBER: 20851124 BUSINESS ADDRESS: STREET 1: CLONSHAUGH BUSINESS AND TECHNOLOGY PARK CITY: COOLOCK, DUBLIN STATE: L2 ZIP: D17 E400 BUSINESS PHONE: (216) 523-5000 MAIL ADDRESS: STREET 1: CLONSHAUGH BUSINESS AND TECHNOLOGY PARK CITY: COOLOCK, DUBLIN STATE: L2 ZIP: D17 E400 FORMER COMPANY: FORMER CONFORMED NAME: Actavis plc DATE OF NAME CHANGE: 20130930 FORMER COMPANY: FORMER CONFORMED NAME: Actavis Ltd DATE OF NAME CHANGE: 20130607 8-K 1 d927973d8k.htm 8-K 8-K
IE false 0001578845 0001578845 2020-05-06 2020-05-06 0001578845 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2020-05-06 2020-05-06 0001578845 agn:FloatingRateNotesDue2020Member 2020-05-06 2020-05-06 0001578845 agn:ZeroPointFiveZeroZeroPercentageNotesDueTwoThousandTwentyOneMember 2020-05-06 2020-05-06 0001578845 agn:OnePointFiveZeroZeroPercentageNotesDueTwoThousandTwentyThreeMember 2020-05-06 2020-05-06 0001578845 agn:OnePointTwoFiveZeroPercentageNotesDueTwoThousandTwentyFourMember 2020-05-06 2020-05-06 0001578845 agn:TwoPointSixTwoFivePercentageNotesDueTwoThousandTwentyEightMember 2020-05-06 2020-05-06 0001578845 agn:TwoPointOneTwoFivePercentageNotesDueTwoThousandTwentyNineMember 2020-05-06 2020-05-06

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): M ay 6, 2020 (May 6, 2020)

 

ALLERGAN PLC

(Exact name of Registrant as specified in its charter)

 

Ireland

  

001-36867

  

98-1114402

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

Clonshaugh Business and Technology Park

Coolock, Dublin, D17 E400, Ireland

(Address of principal executive offices)

(862) 261-7000

Registrant’s telephone number, including area code

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

  ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Ordinary Share, par value $0.0001 per share

  

AGN

  

New York Stock Exchange

Floating rate notes due 2020

  

AGN20A

  

New York Stock Exchange

0.500% notes due 2021

  

AGN21

  

New York Stock Exchange

1.500% notes due 2023

  

AGN23A

  

New York Stock Exchange

1.250% notes due 2024

  

AGN24A

  

New York Stock Exchange

2.625% notes due 2028

  

AGN28

  

New York Stock Exchange

2.125% notes due 2029

  

AGN29

  

New York Stock Exchange

 

 

Item 8.01. Other Matters.

On May 5, 2020, the U.S. Federal Trade Commission (“FTC”) accepted the proposed consent order in connection with the pending transaction (“Transaction”) between Allergan plc (“Allergan”) and AbbVie Inc. (“AbbVie”). The acceptance by the FTC satisfies all required antitrust clearances needed to be obtained for the acquisition of Allergan by AbbVie.

As part of the proposed consent, Allergan has agreed to divest brazikumab, an investigational IL-23 inhibitor in development for autoimmune diseases, to AstraZeneca and Zenpep, a treatment for exocrine pancreatic insufficiency due to cystic fibrosis and other conditions, to Nestle Health Science. Nestle Health Science also will be acquiring Viokace, another pancreatic enzyme preparation, as part of the same transaction.

Additionally, on May 6, 2020, Allergan announced that the High Court of Ireland (the “Court”) has approved the Transaction by means of a scheme of arrangement (the “Scheme”) under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the “Act”).

The Court sanction hearing in relation to the Scheme was held earlier today at which the Court sanctioned the Scheme and confirmed the related reduction of capital.

Completion of the Transaction remains subject to the delivery to, and registration by, the Registrar of Companies in Ireland of copies of (i) the order of the Court sanctioning the Scheme and confirming the related reduction of capital; and (ii) the minute required by Section 86 of the Act in respect of the reduction of capital, each of which is expected to occur on May 8, 2020.

Accordingly, the Scheme is expected to take effect on May 8, 2020.

A copy of the press release relating to the above announcement is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit
  No.  

    

Description

         
 

99.1

   

Press Release, dated May 6, 2020

         
 

104

   

Cover Page Interactive Data File (embedded within the Inline XBRL document)

FORWARD-LOOKING STATEMENTS

This report contains certain forward-looking statements, including with respect to the pending acquisition involving AbbVie and Allergan, Allergan’s divestitures of brazikumab and Zenpep and AbbVie’s, Allergan’s and/or the combined group’s estimated or anticipated future business, performance and results of operations and financial condition, including estimates, forecasts, targets and plans for AbbVie and, following the acquisition, if completed, the combined group. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the possibility that the divestitures and/or the pending acquisition will not be pursued, failure to obtain necessary regulatory approvals or required financing or to satisfy any of the other conditions to the pending acquisition or divestitures, adverse effects on the market price of AbbVie’s shares of common stock or Allergan’s ordinary shares and on AbbVie’s or Allergan’s operating results because of a failure to complete the pending acquisition or divestitures, failure to realize the expected

benefits of the pending acquisition or divestitures, failure to promptly and effectively integrate Allergan’s businesses, negative effects relating to the announcement of the pending acquisition or divestitures or any further announcements relating to the pending acquisition or divestitures or the consummation of the pending acquisition or divestitures on the market price of AbbVie’s shares of common stock or Allergan’s ordinary shares, significant transaction costs and/or unknown or inestimable liabilities, potential litigation associated with the pending acquisition or divestitures, general economic and business conditions that affect the combined companies following the consummation of the pending acquisition, changes in global, political, economic, business, competitive, market and regulatory forces, future exchange and interest rates, changes in tax laws, regulations, rates and policies, future business acquisitions or disposals and competitive developments. These forward-looking statements are based on numerous assumptions and assessments made in light of AbbVie’s or, as the case may be, Allergan’s experience and perception of historical trends, current conditions, business strategies, operating environment, future developments and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking statements in this report could cause AbbVie’s plans with respect to Allergan or AbbVie’s or Allergan’s actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and persons reading this report are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as of the date of this report. Additional information about economic, competitive, governmental, technological and other factors that may affect AbbVie or Allergan is set forth in AbbVie’s and Allergan’s periodic public filings with the U.S. Securities and Exchange Commission, including, but not limited to, AbbVie’s and Allergan’s Annual Report on Form 10-K for the year ended December 31, 2019, and, from time to time, AbbVie’s and Allergan’s other investor communications, in each case, the contents of which are not incorporated by reference into, nor do they form part of, this report.

Any forward-looking statements in this report are based upon information available to AbbVie, Allergan and/or their respective board of directors, as the case may be, as of the date of this report and, while believed to be true when made, may ultimately prove to be incorrect. Subject to any obligations under applicable law, none of AbbVie, Allergan or any member of their respective board of directors undertakes any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. All subsequent written and oral forward-looking statements attributable to AbbVie, Allergan or their respective board of directors or any person acting on behalf of any of them are expressly qualified in their entirety by this paragraph.

Statement Required by the Irish Takeover Rules

The Allergan directors accept responsibility for the information contained in this report. To the best of the knowledge and belief of the Allergan directors (who have taken all reasonable care to ensure such is the case), the information contained in this report for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Allergan plc

     

By:

 

/s/ A. Robert D. Bailey

Name:

 

A. Robert D. Bailey

Title:

 

EVP and Chief Legal Officer and

Corporate Secretary

Dated: May 6, 2020

EX-99.1 2 d927973dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

Announcement relating to the outcome of the Court Sanction Hearing

Allergan plc (NYSE: AGN) (“Allergan”) today announced that the High Court of Ireland (the “Court”) has approved the previously announced proposed acquisition of Allergan by AbbVie Inc. (“AbbVie”) by means of a scheme of arrangement (the “Scheme”) under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the “Act”).

The Court sanction hearing in relation to the Scheme was held earlier today at which the Court sanctioned the Scheme and confirmed the related reduction of capital.

Completion of the acquisition remains subject to the delivery to, and registration by, the Registrar of Companies in Ireland of copies of (i) the order of the Court sanctioning the Scheme and confirming the related reduction of capital; and (ii) the minute required by Section 86 of the Act in respect of the reduction of capital, each of which is expected to occur on May 8, 2020.

Accordingly, the Scheme is expected to take effect on May 8, 2020.

ABOUT ALLERGAN

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.

With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan’s website at www.Allergan.com.

ENQUIRIES

Allergan

 

Media:    Lisa Brown    +1 862 261 7320
Investors:    Manisha Narasimhan, PhD    + 1 862 261 7162

FORWARD-LOOKING STATEMENTS

This announcement contains certain forward-looking statements, including with respect to the pending acquisition involving AbbVie and Allergan and AbbVie’s, Allergan’s and/or the combined group’s estimated or anticipated future business, performance and results of operations and financial condition, including estimates, forecasts, targets and plans for AbbVie and, following the acquisition, if completed, the combined group. The words “believe,” “expect,” “anticipate,” “project” and similar expressions,

among others, generally identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the possibility that the pending acquisition will not be pursued, failure to obtain required financing or to satisfy any of the other conditions to the pending acquisition, adverse effects on the market price of AbbVie’s shares of common stock or Allergan’s ordinary shares and on AbbVie’s or Allergan’s operating results because of a failure to complete the pending acquisition, failure to realize the expected benefits of the pending acquisition, failure to promptly and effectively integrate Allergan’s businesses, negative effects relating to the announcement of the pending acquisition or any further announcements relating to the pending acquisition or the consummation of the pending acquisition on the market price of AbbVie’s shares of common stock or Allergan’s ordinary shares, significant transaction costs and/or unknown or inestimable liabilities, potential litigation associated with the pending acquisition, general economic and business conditions that affect the combined companies following the consummation of the pending acquisition, changes in global, political, economic, business, competitive, market and regulatory forces, future exchange and interest rates, changes in tax laws, regulations, rates and policies, future business acquisitions or disposals and competitive developments. These forward-looking statements are based on numerous assumptions and assessments made in light of AbbVie’s or, as the case may be, Allergan’s experience and perception of historical trends, current conditions, business strategies, operating environment, future developments and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking statements in this announcement could cause AbbVie’s plans with respect to Allergan or AbbVie’s or Allergan’s actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and persons reading this announcement are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as of the date of this announcement. Additional information about economic, competitive, governmental, technological and other factors that may affect AbbVie or Allergan is set forth in AbbVie’s and Allergan’s periodic public filings with the U.S. Securities and Exchange Commission, including, but not limited to, AbbVie’s and Allergan’s Annual Report on Form 10-K for the year ended December 31, 2019, and, from time to time, AbbVie’s and Allergan’s other investor communications, in each case, the contents of which are not incorporated by reference into, nor do they form part of, this announcement.

Any forward-looking statements in this announcement are based upon information available to AbbVie, Allergan and/or their respective board of directors, as the case may be, as of the date of this announcement and, while believed to be true when made, may ultimately prove to be incorrect. Subject to any obligations under applicable law, none of AbbVie, Allergan or any member of their respective board of directors undertakes any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. All subsequent written and oral forward-looking statements attributable to AbbVie, Allergan or their respective board of directors or any person acting on behalf of any of them are expressly qualified in their entirety by this paragraph.

Statement Required by the Irish Takeover Rules

The Allergan directors accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the Allergan directors (who have taken all reasonable care to ensure such is the case), the information contained in this announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of Allergan plc or AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

General

The release, publication or distribution of this announcement in or into certain jurisdictions may be restricted by the laws of those jurisdictions (the “Restricted Jurisdictions”). Accordingly, copies of this announcement and all other documents relating to the acquisition are not being, and must not be, released, published, mailed or otherwise forwarded, distributed or sent in, into or from any Restricted Jurisdictions. Persons receiving such documents (including, without limitation, nominees, trustees and custodians) should observe these restrictions. Failure to do so may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, the companies involved in the acquisition disclaim any responsibility or liability for the violations of any such restrictions by any person.

A copy of this announcement will be available, free of charge (subject to certain restrictions relating to persons resident in Restricted Jurisdictions) on the Allergan website at www.allergan.com. The contents of the Allergan website are not incorporated into, and do not form part of, this announcement.

This announcement has been prepared for the purpose of complying with the laws of Ireland and the Takeover Rules and the information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws of jurisdictions outside of Ireland.

EX-101.SCH 3 agn-20200506.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 agn-20200506_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 agn-20200506_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Address, Country Entity Address, Country Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Fair Value Measured at Net Asset Value Per Share [Member] Fair Value Measured at Net Asset Value Per Share [Member] Floating Rate Notes Due 2020 [Member] Floating Rate Notes Due 2020 [Member] Zero Point Five Zero Zero Percentage Notes Due Two Thousand Twenty One [Member] Zero Point Five Zero Zero Percentage Notes Due Two Thousand Twenty One [Member] One Point Five Zero Zero Percentage Notes Due Two Thousand Twenty Three [Member] One Point Five Zero Zero Percentage Notes Due Two Thousand Twenty Three [Member] One Point Two Five Zero Percentage Notes Due Two Thousand Twenty Four [Member] One Point Two Five Zero Percentage Notes Due Two Thousand Twenty Four [Member] Two Point Six Two Five Percentage Notes Due Two Thousand Twenty Eight [Member] Two Point Six Two Five Percentage Notes Due Two Thousand Twenty Eight [Member] Two Point One Two Five Percentage Notes Due Two Thousand Twenty Nine [Member] Two Point One Two Five Percentage Notes Due Two Thousand Twenty Nine [Member] EX-101.PRE 6 agn-20200506_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 d927973d8k_htm.xml IDEA: XBRL DOCUMENT 0001578845 2020-05-06 2020-05-06 0001578845 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2020-05-06 2020-05-06 0001578845 agn:FloatingRateNotesDue2020Member 2020-05-06 2020-05-06 0001578845 agn:ZeroPointFiveZeroZeroPercentageNotesDueTwoThousandTwentyOneMember 2020-05-06 2020-05-06 0001578845 agn:OnePointFiveZeroZeroPercentageNotesDueTwoThousandTwentyThreeMember 2020-05-06 2020-05-06 0001578845 agn:OnePointTwoFiveZeroPercentageNotesDueTwoThousandTwentyFourMember 2020-05-06 2020-05-06 0001578845 agn:TwoPointSixTwoFivePercentageNotesDueTwoThousandTwentyEightMember 2020-05-06 2020-05-06 0001578845 agn:TwoPointOneTwoFivePercentageNotesDueTwoThousandTwentyNineMember 2020-05-06 2020-05-06 IE false 0001578845 8-K 2020-05-06 ALLERGAN PLC L2 001-36867 98-1114402 Clonshaugh Business and Technology Park Coolock Dublin D17 E400 (862) 261-7000 false false false false false Ordinary Share, par value $0.0001 per share AGN NYSE Floating rate notes due 2020 AGN20A NYSE 0.500% notes due 2021 AGN21 NYSE 1.500% notes due 2023 AGN23A NYSE 1.250% notes due 2024 AGN24A NYSE 2.625% notes due 2028 AGN28 NYSE 2.125% notes due 2029 AGN29 NYSE XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} ZIP 10 0001193125-20-134315-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-134315-xbrl.zip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end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information
May 06, 2020
Document And Entity Information [Line Items]  
Entity Address, Country IE
Amendment Flag false
Entity Central Index Key 0001578845
Document Type 8-K
Document Period End Date May 06, 2020
Entity Registrant Name ALLERGAN PLC
Entity Incorporation State Country Code L2
Entity File Number 001-36867
Entity Tax Identification Number 98-1114402
Entity Address, Address Line One Clonshaugh Business and Technology Park
Entity Address, Address Line Two Coolock
Entity Address, City or Town Dublin
Entity Address, Postal Zip Code D17 E400
City Area Code (862)
Local Phone Number 261-7000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Fair Value Measured at Net Asset Value Per Share [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Ordinary Share, par value $0.0001 per share
Trading Symbol AGN
Security Exchange Name NYSE
Floating Rate Notes Due 2020 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Floating rate notes due 2020
Trading Symbol AGN20A
Security Exchange Name NYSE
Zero Point Five Zero Zero Percentage Notes Due Two Thousand Twenty One [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 0.500% notes due 2021
Trading Symbol AGN21
Security Exchange Name NYSE
One Point Five Zero Zero Percentage Notes Due Two Thousand Twenty Three [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 1.500% notes due 2023
Trading Symbol AGN23A
Security Exchange Name NYSE
One Point Two Five Zero Percentage Notes Due Two Thousand Twenty Four [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 1.250% notes due 2024
Trading Symbol AGN24A
Security Exchange Name NYSE
Two Point Six Two Five Percentage Notes Due Two Thousand Twenty Eight [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 2.625% notes due 2028
Trading Symbol AGN28
Security Exchange Name NYSE
Two Point One Two Five Percentage Notes Due Two Thousand Twenty Nine [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 2.125% notes due 2029
Trading Symbol AGN29
Security Exchange Name NYSE
XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d927973d8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 8, "dts": { "definitionLink": { "local": [ "agn-20200506_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "d927973d8k.htm" ] }, "labelLink": { "local": [ "agn-20200506_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "agn-20200506_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "agn-20200506.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 35, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 6, "memberStandard": 1, "nsprefix": "agn", "nsuri": "http://www.allergan.com/20200506", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d927973d8k.htm", "contextRef": "duration_2020-05-06_to_2020-05-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d927973d8k.htm", "contextRef": "duration_2020-05-06_to_2020-05-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 7, "tag": { "agn_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://www.allergan.com/20200506", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "agn_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://www.allergan.com/20200506", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "agn_FloatingRateNotesDue2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Floating Rate Notes Due 2020 [Member]", "terseLabel": "Floating Rate Notes Due 2020 [Member]" } } }, "localname": "FloatingRateNotesDue2020Member", "nsuri": "http://www.allergan.com/20200506", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "agn_OnePointFiveZeroZeroPercentageNotesDueTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "One Point Five Zero Zero Percentage Notes Due Two Thousand Twenty Three [Member]", "terseLabel": "One Point Five Zero Zero Percentage Notes Due Two Thousand Twenty Three [Member]" } } }, "localname": "OnePointFiveZeroZeroPercentageNotesDueTwoThousandTwentyThreeMember", "nsuri": "http://www.allergan.com/20200506", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "agn_OnePointTwoFiveZeroPercentageNotesDueTwoThousandTwentyFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "One Point Two Five Zero Percentage Notes Due Two Thousand Twenty Four [Member]", "terseLabel": "One Point Two Five Zero Percentage Notes Due Two Thousand Twenty Four [Member]" } } }, "localname": "OnePointTwoFiveZeroPercentageNotesDueTwoThousandTwentyFourMember", "nsuri": "http://www.allergan.com/20200506", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "agn_TwoPointOneTwoFivePercentageNotesDueTwoThousandTwentyNineMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Two Point One Two Five Percentage Notes Due Two Thousand Twenty Nine [Member]", "terseLabel": "Two Point One Two Five Percentage Notes Due Two Thousand Twenty Nine [Member]" } } }, "localname": "TwoPointOneTwoFivePercentageNotesDueTwoThousandTwentyNineMember", "nsuri": "http://www.allergan.com/20200506", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "agn_TwoPointSixTwoFivePercentageNotesDueTwoThousandTwentyEightMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Two Point Six Two Five Percentage Notes Due Two Thousand Twenty Eight [Member]", "terseLabel": "Two Point Six Two Five Percentage Notes Due Two Thousand Twenty Eight [Member]" } } }, "localname": "TwoPointSixTwoFivePercentageNotesDueTwoThousandTwentyEightMember", "nsuri": "http://www.allergan.com/20200506", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "agn_ZeroPointFiveZeroZeroPercentageNotesDueTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Zero Point Five Zero Zero Percentage Notes Due Two Thousand Twenty One [Member]", "terseLabel": "Zero Point Five Zero Zero Percentage Notes Due Two Thousand Twenty One [Member]" } } }, "localname": "ZeroPointFiveZeroZeroPercentageNotesDueTwoThousandTwentyOneMember", "nsuri": "http://www.allergan.com/20200506", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "terseLabel": "Fair Value Measured at Net Asset Value Per Share [Member]" } } }, "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 8 95 1 false 7 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.allergan.com//20200506/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d927973d8k.htm agn-20200506.xsd agn-20200506_def.xml agn-20200506_lab.xml agn-20200506_pre.xml d927973dex991.htm http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true false EXCEL 15 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end